Pharvaris End Period Cash Flow from 2010 to 2024

PHVS Stock  USD 22.29  1.25  5.94%   
Pharvaris End Period Cash Flow yearly trend continues to be comparatively stable with very little volatility. End Period Cash Flow is likely to outpace its year average in 2024. From the period from 2010 to 2024, Pharvaris End Period Cash Flow quarterly data regression had r-value of  0.79 and coefficient of variation of  158.95. View All Fundamentals
 
End Period Cash Flow  
First Reported
2018-03-31
Previous Quarter
343.6 M
Current Value
305.2 M
Quarterly Volatility
124.6 M
 
Covid
Check Pharvaris financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharvaris' main balance sheet or income statement drivers, such as Tax Provision of 634.5 K, Net Interest Income of 223.4 K or Depreciation And Amortization of 54.6 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.41. Pharvaris financial statements analysis is a perfect complement when working with Pharvaris Valuation or Volatility modules.
  
Check out the analysis of Pharvaris Correlation against competitors.

Latest Pharvaris' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Pharvaris BV over the last few years. It is Pharvaris' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pharvaris' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

Pharvaris End Period Cash Flow Regression Statistics

Arithmetic Mean89,419,993
Geometric Mean20,322,661
Coefficient Of Variation158.95
Mean Deviation110,054,075
Median5,385,333
Standard Deviation142,133,494
Sample Variance20201.9T
Range405.7M
R-Value0.79
Mean Square Error8043.3T
R-Squared0.63
Significance0.0004
Slope25,232,084
Total Sum of Squares282827T

Pharvaris End Period Cash Flow History

2024411.1 M
2023391.6 M
2022161.8 M
2021209.4 M
202098.6 M
201920.3 M

About Pharvaris Financial Statements

Pharvaris shareholders use historical fundamental indicators, such as End Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Pharvaris investors may analyze each financial statement separately, they are all interrelated. The changes in Pharvaris' assets and liabilities, for example, are also reflected in the revenues and expenses on on Pharvaris' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
End Period Cash Flow391.6 M411.1 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Pharvaris Stock Analysis

When running Pharvaris' price analysis, check to measure Pharvaris' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharvaris is operating at the current time. Most of Pharvaris' value examination focuses on studying past and present price action to predict the probability of Pharvaris' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharvaris' price. Additionally, you may evaluate how the addition of Pharvaris to your portfolios can decrease your overall portfolio volatility.